论文部分内容阅读
目的观察依那普利联合瑞舒伐他汀治疗糖尿病肾病的临床效果。方法将60例糖尿病肾病患者随机分为观察组和对照组,每组30例。对照组给予单纯依那普利治疗,观察组在对照组基础上加用瑞舒伐他汀治疗,观察2组患者空腹血糖(FPG)、血脂水平、血肌酐(SCr)、24h尿微量白蛋白含量,测量收缩压和舒张压数值。结果治疗后2组FPG值与治疗前比较差异无统计学意义(P>0.05);治疗后2组收缩压和舒张压较治疗前均改善(P<0.05);但治疗后2组间血压值比较差异无统计学意义(P>0.05)。2组患者肾功能指标均较治疗前改善(P<0.05);且观察组肾功能改善情况优于对照组(P<0.05)。观察组治疗后血脂优于对照组(P<0.05)。结论对于糖尿病肾病的临床治疗,采用依那普利联合瑞舒伐他汀临床治疗效果确切,值得推广应用。
Objective To observe the clinical efficacy of enalapril and rosuvastatin in the treatment of diabetic nephropathy. Methods Sixty diabetic patients with diabetic nephropathy were randomly divided into observation group and control group, 30 cases in each group. The control group was given enalapril. The observation group was given rosuvastatin on the basis of the control group. The fasting blood glucose (FPG), blood lipid level, serum creatinine (SCr), 24h urine microalbuminuria Systolic and diastolic values were measured. Results There was no significant difference in FPG value between the two groups after treatment (P> 0.05). The systolic and diastolic blood pressure of the two groups were improved after treatment (P <0.05), but the blood pressure The difference was not statistically significant (P> 0.05). The indexes of renal function in both groups were improved compared with those before treatment (P <0.05). The improvement of renal function in the observation group was better than that in the control group (P <0.05). The observation group after treatment, blood lipids than the control group (P <0.05). Conclusion For the clinical treatment of diabetic nephropathy, enalapril combined with rosuvastatin clinical treatment of exact effect, it is worth promoting the application.